Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
J Infect
    September 2022
  1. HUANG J, Xia L, Zhao Y, Wu X, et al
    Coronavirus disease 2019 vaccination and live birth outcome after fresh embryo transfer.
    J Infect. 2022 Sep 26. pii: S0163-4453(22)00552.
    >> Share

  2. AO G, Li A, Wang Y, Tran C, et al
    The effect of SARS-CoV-2 double vaccination on the outcomes of hemodialysis patients with COVID-19: a meta-analysis.
    J Infect. 2022 Sep 26. pii: S0163-4453(22)00553.
    >> Share

  3. YIN Y, Lin J, Yuan S, Tong S, et al
    A booster shot of vaccine against SARS-CoV-2 should be rigorously promoted and implemented in China.
    J Infect. 2022 Sep 25. pii: S0163-4453(22)00546.
    >> Share

  4. XU QY, Zheng XQ, Jia ZJ, Wu MJ, et al
    Developing new COVID-19 vaccine against the variants is urgently needed rather than boosters: A longitudinal cohort study.
    J Infect. 2022 Sep 12. pii: S0163-4453(22)00539.
    >> Share

  5. MOUSSAOUI ME, Desmecht S, Tashkeev A, Lambert N, et al
    Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naive people living with HIV.
    J Infect. 2022 Sep 9. pii: S0163-4453(22)00534.
    >> Share

  6. ATTI A, Insalata F, Carr EJ, Otter AD, et al
    Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: a nested case-control within the SIREN study.
    J Infect. 2022 Sep 8. pii: S0163-4453(22)00535.
    >> Share

  7. BEKKAT-BERKANI R, Fragapane E, Preiss S, Rappuoli R, et al
    Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.
    J Infect. 2022 Sep 7. pii: S0163-4453(22)00530.
    >> Share

  8. SHI T, Dai M, Liu F, Hu J, et al
    Dynamics of immune responses to inactivated COVID-19 vaccination over 8 months in China.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00521.
    >> Share

  9. DIMEGLIO C, Tremeaux P, Herin F, Da-Silva I, et al
    Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00522.
    >> Share

    August 2022
  10. GIDARI A, Schiaroli E, Sabbatini S, Bastianelli S, et al
    Impact of SARS-CoV-2 Omicron Variants on Serum Neutralization in a Cohort of Healthcare Workers Vaccinated with BNT162b2.
    J Infect. 2022 Aug 25. pii: S0163-4453(22)00507.
    >> Share

  11. LI K, Ruan F, Zhao Z, Guo Z, et al
    Comparative analysis of transmission and vaccine effectiveness in Omicron and Delta variant outbreaks in China.
    J Infect. 2022 Aug 22. pii: S0163-4453(22)00502.
    >> Share

  12. WAN EYF, Mok AHY, Yan VKC, Wang B, et al
    Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study.
    J Infect. 2022 Aug 16. pii: S0163-4453(22)00472.
    >> Share

    July 2022
  13. NOH JY, Cheong HJ, Kim WJ, Choi JY, et al
    Robust neutralizing antibody responses after single-dose BNT162b2 vaccination at long intervals from prior SARS-CoV-2 infection and ceiling effect with repeated vaccination: Running title: Optimal vaccination interval and ceiling effect.
    J Infect. 2022 Jul 31. pii: S0163-4453(22)00456.
    >> Share

  14. HAGIYA H, Hikita T, Habu T, Asada M, et al
    Poor vaccine responsiveness towards third-dose mRNA vaccine of COVID-19 in Japanese older people.
    J Infect. 2022 Jul 11. pii: S0163-4453(22)00413.
    >> Share

  15. YAN Y, Davgadorj C, Lyu C, Zhang S, et al
    Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: a cross-sectional study.
    J Infect. 2022 Jul 5. pii: S0163-4453(22)00407.
    >> Share

    June 2022
  16. XIAO J, Zhu Q, Yang F, Zeng S, et al
    The impact of enterovirus A71 vaccination program on hand, foot, and mouth disease in Guangdong, China:a longitudinal surveillance study.
    J Infect. 2022 Jun 26. pii: S0163-4453(22)00376.
    >> Share

  17. YIN Y, Li X, Qian C, Cheng B, et al
    Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study.
    J Infect. 2022 Jun 24. pii: S0163-4453(22)00374.
    >> Share

  18. NIYOMNAITHAM S, Toh ZQ, Licciardi PV, Wongprompitak P, et al
    Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: a randomized trial.
    J Infect. 2022 Jun 18. pii: S0163-4453(22)00370.
    >> Share

  19. LAZARUS R, Taucher C, Brown C, Corbic I, et al
    Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
    J Infect. 2022 Jun 16. pii: S0163-4453(22)00361.
    >> Share

  20. WORSLEY CM, van der Mescht MA, Hoffman D, Meyer PWA, et al
    Decline in antibody responses to SARS-CoV-2 post-vaccination poses a risk to health care workers.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00360.
    >> Share

  21. KANG SW, Kim JY, Park H, Lim SY, et al
    Comparison of outward transmission potential between vaccinated and partially vaccinated or unvaccinated individuals with the SARS-CoV-2 delta variant infection.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00355.
    >> Share

  22. XU QY, Li QL, Jia ZJ, Wu MJ, et al
    Is the fourth COVID-19 vaccine dose urgently needed? Revelation from a prospective cohort study.
    J Infect. 2022 Jun 9. pii: S0163-4453(22)00356.
    >> Share

  23. CHEN CH, Janapatla RP, Su LH, Li HC, et al
    Incidence rates, emerging serotypes and genotypes, and antimicrobial susceptibility of pneumococcal disease in Taiwan: A multi-center clinical microbiological study after PCV13 implementation.
    J Infect. 2022;84:788-794.
    >> Share

  24. PAPAILIOU S, Soldatou A, Marmarinos A, Avgeris M, et al
    Inadequate protection against measles and rubella among pregnant women in Greece during the last measles outbreak.
    J Infect. 2022;84:e95-e97.
    >> Share

    May 2022
  25. NISHIKIMI A, Watanabe K, Watanabe A, Yasuoka M, et al
    Immune responses to COVID-19 vaccine BNT162b2 in workers at a research institute in Japan: 6-month follow-up survey.
    J Infect. 2022 May 20. pii: S0163-4453(22)00307.
    >> Share

  26. ZHANG YM, Liu XZ, Lin MM, Zan JC, et al
    Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients.
    J Infect. 2022 May 9. pii: S0163-4453(22)00260.
    >> Share

  27. VAN GRONINGEN KM, Dao BL, Gounder P
    Declines in invasive pneumococcal disease (IPD) during the COVID-19 pandemic in Los Angeles county.
    J Infect. 2022 May 9. pii: S0163-4453(22)00259.
    >> Share

  28. DIMEGLIO C, Migueres M, Chapuy-Regaud S, Da-Silva I, et al
    Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response.
    J Infect. 2022 May 7. pii: S0163-4453(22)00258.
    >> Share

  29. MARSAY L, Dold C, Paterson GK, Yamaguchi Y, et al
    Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.
    J Infect. 2022;84:658-667.
    >> Share

    April 2022
  30. JIMENEZ D, Martinez-Sanz J, Sainz T, Calvo C, et al
    Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00248.
    >> Share

  31. YADAV PD, Sapkal GN, Sahay RR, Patil DY, et al
    Reduced neutralizing antibody response in naive Covishield vaccinees against Omicron emphasizes booster vaccination.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00213.
    >> Share

  32. PANDIT P, Bhatt P, Sahay RR, Joshi Y, et al
    A case of breakthrough infection with SARS-CoV-2 Delta derivative and reinfection with Omicron variant in a fully vaccinated health care professional.
    J Infect. 2022 Apr 18. pii: S0163-4453(22)00205.
    >> Share

  33. LIU X, Munro APS, Feng S, Janani L, et al
    Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00200.
    >> Share

  34. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    Serum C reactive protein predicts humoral response after BNT162b2 booster administration.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00197.
    >> Share

  35. YADAV PD, Sahay RR, Agrawal S, Shete A, et al
    Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00193.
    >> Share

  36. LIU Y, Li P, Yang L, Li P, et al
    High vaccination coverage slows down genetic diversity of SARS-CoV-2.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00191.
    >> Share

  37. CHENG CY, Hsiao SH, Fang TC, Lin YC, et al
    SARS-CoV2 Antibody Response After a Third Dose of Heterologous ChAdOx1 nCoV-19 and Moderna Vaccine in Chronic Dialysis Patients.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00190.
    >> Share

  38. LIN J, Dobbins T, Wood JG, Bernardo C, et al
    Impact of a national immunisation program on herpes zoster incidence in Australia.
    J Infect. 2022;84:537-541.
    >> Share

    March 2022
  39. SCHILDGEN V, Lusebrink J, Schildgen O
    Compulsary SARS-CoV-2 (booster-) vaccination in healthcare facilities can not replace personal protection measures while dealing with vulnarable individuals.
    J Infect. 2022 Mar 23. pii: S0163-4453(22)00173.
    >> Share

  40. YADAV PD, Sapkal GN, Sahay RR, Patil DY, et al
    Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naive vaccinees.
    J Infect. 2022 Mar 19. pii: S0163-4453(22)00170.
    >> Share

  41. DIMEGLIO C, Loubes JM, Migueres M, Saune K, et al
    Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants.
    J Infect. 2022 Mar 17. pii: S0163-4453(22)00140.
    >> Share

  42. XIANG B, Yang L, Ye Z, Ren T, et al
    Vaccination of Susceptible Animals Against SARS-CoV-2.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00131.
    >> Share

  43. FERRE VM, Lebourgeois S, Chenane HR, Menidjel R, et al
    Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00126.
    >> Share

  44. BONNET B, Chabrolles H, Archimbaud C, Brebion A, et al
    Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00132.
    >> Share

  45. GIMENEZ E, Albert E, Burgos JS, Peiro S, et al
    SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty(R) COVID-19 vaccine.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00124.
    >> Share

  46. BONGIOVANNI M, Spada E, De Angelis C, Liuzzi G, et al
    SARS-CoV-2: about reinfection, vaccination and neutralizing antibodies.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00125.
    >> Share

  47. SYED MA DR, A/Qotba HA Dr, Al Nuaimi AS Dr
    Effectiveness of COVID-19 vaccines in Qatar.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00121.
    >> Share

  48. SCHALTZ-BUCHHOLZER F, Bjerregard Oland C, Berendsen M, Bjerregaard-Andersen M, et al
    Maternal BCG primes for enhanced health benefits in the newborn.
    J Infect. 2022;84:321-328.
    >> Share

  49. AU WY, Ye C, Briner SL, Suarez GD, et al
    Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00123.
    >> Share

    February 2022
  50. PUTRI DU, Lin CF, Hung CS, Huang CK, et al
    Distinct B and NKT cell Responses Shape the Delayed Response to ChAdOx1 nCoV-19 Vaccine in End-Stage Renal Disease.
    J Infect. 2022 Feb 28. pii: S0163-4453(22)00116.
    >> Share

  51. HAYASHI JY, Simizo A, Miyamoto JG, Costa LVS, et al
    Humoral and Cellular Responses to Vaccination with Homologous CoronaVac or ChAdOx1 and Heterologous Third Dose with BNT162b2.
    J Infect. 2022 Feb 27. pii: S0163-4453(22)00115.
    >> Share

  52. TANG K, Wu X, Luo Y, Wei Z, et al
    Meta-analysis of Immunologic response after COVID-19 mRNA vaccination in solid organ transplant recipients.
    J Infect. 2022 Feb 19. pii: S0163-4453(22)00081.
    >> Share

  53. SAHAY RR, Patil DY, Sapkal GN, Deshpande GR, et al
    SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera.
    J Infect. 2022 Feb 19. pii: S0163-4453(22)00082.
    >> Share

  54. FERRI S, Polidoro A, Ciacciarelli M, Ceratti U, et al
    Decline of immune humoral response after BNT162b2 Vaccine.
    J Infect. 2022 Feb 17. pii: S0163-4453(22)00076.
    >> Share

  55. TRE-HARDY M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, et al
    Assessment 2 months after the administration of a 3rd dose mRNA: A new variant-adapted vaccine is expected.
    J Infect. 2022 Feb 15. pii: S0163-4453(22)00073.
    >> Share

  56. LIU F, Wang H, Cao Y, Zhang N, et al
    Effectiveness of varicella vaccine in 1-year-old children: a matched case-control study.
    J Infect. 2022 Feb 11. pii: S0163-4453(22)00069.
    >> Share

  57. WESTROP SJ, Whitaker HJ, Powell AA, Power L, et al
    Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England.
    J Infect. 2022 Feb 4. pii: S0163-4453(22)00055.
    >> Share

  58. ESTOFOLETE CF, Fares GF, Banho CA, Sacchetto L, et al
    Predictors of death in COVID-19 vaccine breakthrough infections in Brazil.
    J Infect. 2022 Feb 2. pii: S0163-4453(22)00059.
    >> Share

    January 2022
  59. XU W, Tang J, Chen C, Wang C, et al
    Safety and Efficacy of the Covid-19 Vaccine in children andor adolescents: A meta-analysis.
    J Infect. 2022 Jan 30. pii: S0163-4453(22)00050.
    >> Share

  60. MATTIUZZI C, Lippi G
    COVID-19 vaccines efficacy in preventing or limiting SARS-CoV-2 infections.
    J Infect. 2022 Jan 30. pii: S0163-4453(22)00051.
    >> Share

  61. MENSAH AA, Lacy J, Stowe J, Seghezzo G, et al
    Evaluation of disease severity during SARS-COV-2 reinfection, January 2020 to April 2021, England: an observational study.
    J Infect. 2022 Jan 24. pii: S0163-4453(22)00010.
    >> Share

  62. DUCLOUX D, Bamoulid J, Chabannes M, Colladant M, et al
    Current vaccine strategies against SARS_CoV-2 only poorly protect kidney transplant recipients.
    J Infect. 2022 Jan 21. pii: S0163-4453(22)00020.
    >> Share

  63. FAUSTINI S, Shields A, Banham G, Wall N, et al
    Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00002.
    >> Share

  64. YANG Y, Gong X, Yang L, Li J, et al
    Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections or vaccinees.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00005.
    >> Share

  65. DE MICHELENA P, Torres I, Albert E, Bracho A, et al
    Impact of time elapsed since full vaccination on SARS-CoV-2 RNA load in Delta-variant breakthrough COVID-19.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00007.
    >> Share

  66. WHITAKER HJ, Tsang RS, Byford R, Andrews NJ, et al
    Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups.
    J Infect. 2022 Jan 3. pii: S0163-4453(21)00664.
    >> Share

  67. MARRAMS ARM, Kobayashi T, Suzuki H, Alsuhaibani M, et al
    Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis.
    J Infect. 2022 Jan 1. pii: S0163-4453(21)00658.
    >> Share

    December 2021
  68. MIN JY, Mwakingwe-Omari A, Riley M, Molo LY, et al
    The Adjuvanted Recombinant Zoster Vaccine Co-Administered with the 13-valent Pneumococcal Conjugate Vaccine in Adults Aged >/=50 Years: a Randomized Trial.
    J Infect. 2021 Dec 25. pii: S0163-4453(21)00651.
    >> Share

  69. COSTA R, Olea B, Bracho MA, Albert E, et al
    RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00641.
    >> Share

  70. MANOLACHE NG, Ursachi V, Scohy A, Desmet C, et al
    Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases.
    J Infect. 2021 Dec 14. pii: S0163-4453(21)00597.
    >> Share

  71. MAK WA, Koeleman JGM, van der Vliet M, Keuren F, et al
    SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study.
    J Infect. 2021 Dec 9. pii: S0163-4453(21)00593.
    >> Share

    November 2021
  72. OESER C, Whitaker H, Linley E, Borrow R, et al
    Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.
    J Infect. 2021 Nov 30. pii: S0163-4453(21)00584.
    >> Share

  73. LUCIDARME J, Bai X, Lekshmi A, Clark SA, et al
    Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - first real-world data: Meningococcal B following 4CMenB.
    J Infect. 2021 Nov 25. pii: S0163-4453(21)00579.
    >> Share

  74. ALDERSON MR, Arkwright PD, Bai X, Black S, et al
    Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review.
    J Infect. 2021 Nov 24. pii: S0163-4453(21)00578.
    >> Share

  75. LEBOURGEOIS S, Menidjel R, Chenane HR, Ferre VM, et al
    Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.
    J Infect. 2021 Nov 19. pii: S0163-4453(21)00556.
    >> Share

  76. GIMENEZ E, Alberola J, Torres I, Albert E, et al
    Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty(R) COVID-19 vaccine.
    J Infect. 2021 Nov 2. pii: S0163-4453(21)00542.
    >> Share

    October 2021
  77. CHONG Y, Tani N, Goto T, Yonekawa A, et al
    Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents.
    J Infect. 2021 Oct 20. pii: S0163-4453(21)00508.
    >> Share

  78. GUPTA A, Bhoyar RC, Mirza S, Jolly B, et al
    SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker.
    J Infect. 2021 Oct 19. pii: S0163-4453(21)00506.
    >> Share

  79. ANIS E, Haas EJ, Indenbaum V, Singer SR, et al
    A prolonged, nationwide measles outbreak despite very high vaccination coverage in Israel, 2018-19.
    J Infect. 2021 Oct 6. pii: S0163-4453(21)00497.
    >> Share

    September 2021
  80. FERRE VM, Lebourgeois S, Menidjel R, Collin G, et al
    Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine.
    J Infect. 2021 Sep 29. pii: S0163-4453(21)00488.
    >> Share

  81. LUNA-MUSCHI A, Borges IC, de Faria E, Barboza AS, et al
    Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: a prospective cohort study of vaccinated and unvaccinated healthcare workers.
    J Infect. 2021 Sep 16. pii: S0163-4453(21)00474.
    >> Share

    August 2021
  82. TRE-HARDY M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, et al
    Six-month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 vaccine in healthcare workers: A third dose is expected.
    J Infect. 2021 Aug 23. pii: S0163-4453(21)00433.
    >> Share

  83. WEISSMAN YL, Cooper L, Sternbach N, Ashkenazi-Hoffnung L, et al
    Clinical efficacy and safety of high dose trivalent influenza vaccine in adults and immunosuppressed populations -a systematic review and meta-analysis.
    J Infect. 2021 Aug 20. pii: S0163-4453(21)00417.
    >> Share

  84. GODOY P, Garcia-Cenoz M, Rius C, Munoz-Almagro C, et al
    Effectiveness of maternal pertussis vaccination in protecting newborn: a matched case-control study: Maternal pertussis vaccination in protecting newborn.
    J Infect. 2021 Aug 15. pii: S0163-4453(21)00404.
    >> Share

  85. DOUXFILS J, Gillot C, Mullier F, Favresse J, et al
    Post-SARS-CoV-2 vaccination specific antibody decrease - Thresholds for determining seroprevalence and seroneutralization differ.
    J Infect. 2021 Aug 15. pii: S0163-4453(21)00405.
    >> Share

  86. ALLEN N, Brady M, Martin AIC, Domegan L, et al
    Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals.
    J Infect. 2021 Aug 9. pii: S0163-4453(21)00394.
    >> Share

  87. YAHI N, Chahinian H, Fantini J
    Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination ?
    J Infect. 2021 Aug 9. pii: S0163-4453(21)00392.
    >> Share

  88. Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals.
    J Infect. 2021 Aug 6. pii: S0163-4453(21)00388.
    >> Share

  89. GOBBI F, Buonfrate D, Silva R, Martini D, et al
    Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine: SARS-CoV-2 infection early after the first vaccine dose.
    J Infect. 2021 Aug 6. pii: S0163-4453(21)00390.
    >> Share

  90. Predominance of Delta variant among the COVID-19 vaccinated and unvaccinated individuals, India, May 2021.
    J Infect. 2021 Aug 5. pii: S0163-4453(21)00387.
    >> Share

  91. UDDEN F, Runow E, Slotved HC, Fuursted K, et al
    Characterization of Streptococcus pneumoniae detected in clinical respiratory tract samples in southern Sweden 2 to 4 years after introduction of PCV13.
    J Infect. 2021;83:190-196.
    >> Share

    July 2021
  92. WANG H, Liu F, Cao Y, Zhang N, et al
    Epidemiological characteristics of Varicella before and after the implementation of two-dose vaccination schedule in Chaoyang District, Beijing, 2007-2019.
    J Infect. 2021 Jul 29. pii: S0163-4453(21)00378.
    >> Share

  93. BENE MC, Bittencourt MC, Chevallier P
    Post-SARS-CoV-2 vaccination specific antibody decrease : let's get the half-full glass perspective.
    J Infect. 2021 Jul 28. pii: S0163-4453(21)00370.
    >> Share

  94. EBANKS D, Faustini S, Shields A, Parry H, et al
    Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays.
    J Infect. 2021 Jul 26. pii: S0163-4453(21)00363.
    >> Share

  95. GIDARI A, Sabbatini S, Bastianelli S, Pierucci S, et al
    Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.
    J Infect. 2021 Jul 25. pii: S0163-4453(21)00362.
    >> Share

    Crossing the Rubicon: a Fine Line between Waiting and Vaccinating Adolescents against COVID-19.
    J Infect. 2021 Jul 21. pii: S0163-4453(21)00357.
    >> Share

  97. MOMBELLI M, Hoschler K, Cavassini M, Pascual M, et al
    Seasonal Trivalent Inactivated Influenza Vaccine with Topical Imiquimod in Immunocompromised Patients: a Randomized Controlled Trial.
    J Infect. 2021 Jul 20. pii: S0163-4453(21)00353.
    >> Share

  98. ANGELETTI S, Giovanetti M, Fogolari M, De Florio L, et al
    Detection of a SARS-CoV-2 P.1.1 variant lacking N501Y in a vaccinated Health Care worker in Italy.
    J Infect. 2021 Jul 5. pii: S0163-4453(21)00325.
    >> Share

  99. FAVRESSE J, Douxfils J
    Importance of Sample Dilution in the Evaluation of the Antibody Response after SARS-CoV-2 Vaccination.
    J Infect. 2021 Jul 4. pii: S0163-4453(21)00327.
    >> Share

    June 2021
  100. HSU L, Wisplinghoff H, Kossow A, Hurrass J, et al
    Limited protection against SARS-CoV-2 infection and virus transmission after mRNA vaccination.
    J Infect. 2021 Jun 29. pii: S0163-4453(21)00320.
    >> Share

  101. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers.
    J Infect. 2021 Jun 29. pii: S0163-4453(21)00321.
    >> Share

  102. TRE-HARDY M, Cupaiolo R, Wilmet A, Beukinga I, et al
    Waning antibodies in SARS-CoV-2 naive vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.
    J Infect. 2021 Jun 20. pii: S0163-4453(21)00314.
    >> Share

  103. DIMEGLIO C, Herin F, Miedouge M, Da-Silva I, et al
    One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection.
    J Infect. 2021 Jun 17. pii: S0163-4453(21)00312.
    >> Share

  104. KWOK KO, McNeil EB, Tsoi MTF, Wei VWI, et al
    Will achieving herd immunity be a road to success to end the COVID-19 pandemic?
    J Infect. 2021 Jun 9. pii: S0163-4453(21)00287.
    >> Share

  105. AKPOLAT T, Uzun O
    J Infect. 2021 Jun 8. pii: S0163-4453(21)00285.
    >> Share

    May 2021
  106. RAW RK, Kelly C, Rees J, Wroe C, et al
    Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination.
    J Infect. 2021 May 29. pii: S0163-4453(21)00277.
    >> Share

  107. PEZZATI L, Giacomelli A, Mileto D, Conti F, et al
    Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: a cross-sectional study.: Rapid lateral-flow immunochromatographic tests after BNT162b2 vaccine.
    J Infect. 2021 May 29. pii: S0163-4453(21)00271.
    >> Share

  108. BUTT AA, Khan T, Yan P, Shaikh OS, et al
    Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination.
    J Infect. 2021 May 28. pii: S0163-4453(21)00263.
    >> Share

  109. J BP, Jolly B, John N, Bhoyar RC, et al
    Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India.
    J Infect. 2021 May 24. pii: S0163-4453(21)00260.
    >> Share

  110. WHITAKER HJ, Elgohari S, Rowe C, Otter AD, et al
    Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021.
    J Infect. 2021 May 11. pii: S0163-4453(21)00224.
    >> Share

  111. SANSONE E, Tiraboschi M, Sala E, Albini E, et al
    Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy.
    J Infect. 2021 May 6. pii: S0163-4453(21)00225.
    >> Share

    April 2021
  112. GARVEY MI, Wilkinson MAC, Holden E, Shields A, et al
    Early observations on the impact of a healthcare worker COVID-19 vaccination programme at a major UK tertiary centre.
    J Infect. 2021 Apr 29. pii: S0163-4453(21)00214.
    >> Share

  113. MARTINON-TORRES F, Banzhoff A, Azzari C, De Wals P, et al
    Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination: Real-world effectiveness of MenB vaccination.
    J Infect. 2021 Apr 29. pii: S0163-4453(21)00218.
    >> Share

  114. DONADIO C, Rainone A, Gouronnec A, Belmin J, et al
    Asymptomatic COVID-19 cases among older patients despite BNT162b2 vaccination: a case series in a geriatric rehabilitation ward during an outbreak.
    J Infect. 2021 Apr 11. pii: S0163-4453(21)00167.
    >> Share

  115. LODI L, Moriondo M, Nieddu F, Ricci S, et al
    Molecular typing of group B Neisseria meningitidis'subcapsular antigens directly on biological samples demonstrates epidemiological congruence between culture-positive and -negative cases: A surveillance study of invasive disease over a 13-year period
    J Infect. 2021;82:28-36.
    >> Share

    February 2021
  116. ABAD R, Garcia-Amil C, Navarro C, Martin E, et al
    Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: evolution of the vaccine antigen factor H binding protein (FHbp).
    J Infect. 2021 Feb 18. pii: S0163-4453(21)00087.
    >> Share

  117. BAO HL, Jin C, Wang S, Song Y, et al
    Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: A nationwide population-based study.
    J Infect. 2021 Feb 18. pii: S0163-4453(21)00084.
    >> Share

  118. ANTONELLI M, Capdevila J, Chaudhari A, Granerod J, et al
    Optimal symptom combinations to aid COVID-19 case identification: analysis from a community-based, prospective, observational cohort.
    J Infect. 2021 Feb 13. pii: S0163-4453(21)00079.
    >> Share

    December 2020
  119. ZENG H, Yi L, Chen X, Zhou H, et al
    First detection of EV-A71 genotype C1 in China Emergence of a non vaccine-cognate enterovirus A71 genotype C1 in mainland China.
    J Infect. 2020 Dec 26. pii: S0163-4453(20)30782.
    >> Share

    November 2020
  120. LEVI M, Miglietta A, Romeo G, Bartolacci S, et al
    Letter in response to article in Journal of Infection: Impact of Routine Infant BCG Vaccination on COVID-19.
    J Infect. 2020 Nov 25. pii: S0163-4453(20)30718.
    >> Share

  121. HAMED E, Alnuaimi AS, Syed MA, Elhamid MA, et al
    Clinical characteristics of 51815 patients presenting with positive and negative SARS-CoV-2 swab results in primary health care settings.
    J Infect. 2020 Nov 13. pii: S0163-4453(20)30709.
    >> Share

  122. AYE AMM, Bai X, Borrow R, Bory S, et al
    Meningococcal disease surveillance in the Asia-Pacific region (2020): The global meningococcal initiative.
    J Infect. 2020;81:698-711.
    >> Share

    October 2020
  123. SUAYA JA, Mendes RE, Sings HL, Arguedas A, et al
    Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 20092017.
    J Infect. 2020;81:557-566.
    >> Share

  124. SMITH EL, Wheeler I, Adler H, Ferreira DM, et al
    Upper airways colonisation of Streptococcus pneumoniae in adults aged 60 years and older: A systematic review of prevalence and individual participant data meta-analysis of risk factors.
    J Infect. 2020;81:540-548.
    >> Share

    August 2020
  125. GLATMAN-FREEDMAN A, Kaufman Z, Applbaum Y, Dichtiar R, et al
    Respiratory Syncytial Virus hospitalization burden: a nation-wide population-based analysis, 2000-2017.
    J Infect. 2020;81:297-303.
    >> Share

  126. GOMEZ-RIAL J, Rivero-Calle I, Salas A, Martinon-Torres F, et al
    Rotavirus and autoimmunity.
    J Infect. 2020;81:183-189.
    >> Share

    July 2020
  127. NYAZIKA TK, Law A, Swarthout TD, Sibale L, et al
    Influenza-like illness is associated with high pneumococcal carriage density in Malawian children.
    J Infect. 2020 Jul 22. pii: S0163-4453(20)30495.
    >> Share

    May 2020
  128. DEGHMANE AE, Haeghebaert S, Hong E, Jousset A, et al
    Emergence of new genetic lineage, ST-9316, of Neisseria meningitidis group W in Hauts-de-France region, France 2013-2018.
    J Infect. 2020;80:519-526.
    >> Share

    March 2020
  129. BEEBEEJAUN K, Parikh SR, Campbell H, Gray S, et al
    Invasive meningococcal disease: Timing and cause of death in England, 2008-2015.
    J Infect. 2020;80:286-290.
    >> Share

    February 2020
  130. CAMPBELL H, Andrews N, Parikh S, Ribeiro S, et al
    Variable clinical presentation by the main capsular groups causing invasive meningococcal disease in England.
    J Infect. 2020;80:182-189.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016